As part of the Company’s strategic shift into the OTC marketplace, it has withdrawn its investigational new drug application for XYNGARI with FDA. The Company believes this strategic decision will provide greater flexibility to leverage the many novel features and benefits of its Spongilla technology in a variety of skin care products for the OTC marketplace. The Company plans to provide regular updates on the progress of this strategic shift and its upcoming OTC product launches, with the first product launch planned for mid-2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA: